Search ABUS
Arbutus Biopharma Corp
Nasdaq · CIK 1447028
Last close4.45
Daily change-0.11 (-2.41%)
10 Years gain+27.87%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ABUS · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
62.9Momentum
100.0Acceleration
100.0Confidence
91.0Annual Revenue15
Quarterly Revenue53
Annual CFO15
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth7.7 / 25
Quality17.0 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 1466.1492 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM2,909.09%OK
Revenue CAGR 3Y-28.8%OK
Gross Margin100%OK
Operating Margin81.38%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC145.09%OK
Incremental Operating Margin 3Y137.12%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.55%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $14.08M | $14.08M | -$38.16M | -$39.64M | -$39.64M | 100% | -270.97% | -281.45% | n/a | 191.6M |
| 2025 FY Dec 31, 2024 | $6.17M | $6.17M | -$76.32M | -$64.85M | -$65.03M | 100% | -1,236.74% | -1,053.83% | n/a | 185.61M |
| 2024 FY Dec 31, 2023 | $18.14M | $18.14M | -$78.10M | -$85.94M | -$86.94M | 100% | -430.53% | -479.27% | n/a | 165.96M |
| 2023 FY Dec 31, 2022 | $39.02M | $39.02M | -$65.46M | -$35.36M | -$35.87M | 100% | -167.75% | -91.92% | -2,546.68% | 150.94M |
| 2022 FY Dec 31, 2021 | $10.99M | $10.99M | -$73.52M | -$67.53M | -$68.34M | 100% | -669.11% | -621.96% | n/a | 106.24M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $191.41M | sum latest 4 fiscal quarters Revenue | OK | 0001447028-26-000045, 0001447028-25-000126 |
| Revenue Growth TTM | 2,909.09% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001447028-26-000045, 0001447028-25-000126 |
| Revenue CAGR 3Y | -28.8% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001447028-26-000017 |
| Revenue CAGR 5Y | 15.29% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001447028-26-000017 |
| Gross Profit CAGR 3Y | -28.8% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001447028-26-000017 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001447028-26-000045, 0001447028-25-000126 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001447028-26-000045, 0001447028-25-000126 |
| Operating Margin | 81.38% | Operating Income / Revenue | OK | 0001447028-26-000045, 0001447028-25-000126 |
| ROIC | 145.09% | NOPAT / Average Invested Capital | OK | 0001447028-26-000045, 0001447028-25-000126 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001447028-26-000045 |
| Current Ratio | 81.42x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.97 | Revenue / Diluted Shares | OK | 0001447028-26-000045, 0001447028-25-000126 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |